Perfood announced completing a €5 million Series A round led by Boehringer Ingelheim Venture Fund

Perfood, a Lübeck, Germany-based SAAS developer of digital therapeutics, announced that it raised funding of €5 million ($6M) in a Series A round.

The money was raised from German and Swiss investors led by Boehringer Ingelheim Venture Fund, and joined by German family office UV-Cap and Swiss investment platform investiere.

Dr. Oliver Reuss will join Perfood’s advisory board for Boehringer Ingelheim Venture Fund together with Nicholas Vetter of UV-Cap, Jochen Brüggen, representing Perfood’s Seed inves-tors, and Dominik Burziwoda.

The proceeds will be used for launching Perfood’s first prescription therapeutic sinCephalea for the treatment of migraine and to prepare the expansion of the technology into other indications. This includes conductions of clinical studies to advance its pipeline of digital therapeutics products.  

Perfood, founded in 2017 by CEO Dominik Burziwoda, is developing digital therapy programs based on personalized, blood sugar-stabilizing nutrition. The personalized nutrition intervention is enhanced with targeted behavioral modu-lation, such as features for adherence management and patient education. For that, Perfood tracks nutrition, activity, symptoms, and medication as well as glycemic responses for a limited period of two weeks, followed by a digital patient support program.